Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

782
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
782
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.1K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.1K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

1.2K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.2K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

1.1K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.1K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

2.7K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
2.7K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

481
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
481

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduced Prevalence of Impaired Awareness of Hypoglycemia Over Two Decades in Population-Based Samples of Youth With Type 1 Diabetes.

Diabetes care·2026
Same author

Diabetic Retinopathy Outcomes and Early Worsening of Diabetic Retinopathy in Adolescents and Young Adults With Type 1 Diabetes Following Rapid and Large Glycemic Improvements After Commencing Automated Insulin Delivery.

Journal of diabetes science and technology·2026
Same author

Health Service Leaders' Perspectives on Type 1 Diabetes Models of Care for Children and Young Adults in Australia: A Mixed-Methods Study.

Journal of diabetes research·2026
Same author

Predicting mortality with machine learning & biomarkers: A cohort analysis from aerosolized β₂-agonist for treatment of acute lung injury (ALTA) trial.

Physiological reports·2026
Same author

Validity and Discriminative Value of Activity Questionnaires in Youth with Type 1 Diabetes.

Hormone research in paediatrics·2025
Same author

Automated Insulin Delivery Is Associated with Reduced Hospital Admissions and Costs for Acute Diabetes Complications in Children with Type 1 Diabetes.

Diabetes technology & therapeutics·2025

Related Experiment Video

Updated: Oct 14, 2025

Pressure Controlled Ventilation to Induce Acute Lung Injury in Mice
07:55

Pressure Controlled Ventilation to Induce Acute Lung Injury in Mice

Published on: May 5, 2011

18.5K

Beta-Adrenergic Blockade in Critical Illness.

Rebecca Bruning1, Hannah Dykes1, Timothy W Jones1

  • 1Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Augusta, GA, United States.

Frontiers in Pharmacology
|November 1, 2021
PubMed
Summary

Beta-blockers (BB) may improve outcomes in critical illnesses like sepsis and trauma. Evidence suggests they benefit hemodynamic and metabolic parameters, potentially reducing mortality and improving healing and neurologic recovery.

Keywords:
beta-blockerscritical illnessesmololhemodynamicssepsistachyarrhythmia

More Related Videos

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

3.1K
Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness
09:17

Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness

Published on: May 2, 2017

9.1K

Related Experiment Videos

Last Updated: Oct 14, 2025

Pressure Controlled Ventilation to Induce Acute Lung Injury in Mice
07:55

Pressure Controlled Ventilation to Induce Acute Lung Injury in Mice

Published on: May 5, 2011

18.5K
Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

3.1K
Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness
09:17

Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness

Published on: May 2, 2017

9.1K

Area of Science:

  • Critical Care Medicine
  • Pharmacology
  • Cardiovascular Physiology

Background:

  • Catecholamine upregulation is a key feature of critical illness, and sustained beta-adrenergic stimulation can cause adverse effects.
  • Beta-blockers (BB) are being investigated for their potential therapeutic roles in critical care settings.

Purpose of the Study:

  • To review the existing evidence on the pharmacotherapeutic role of beta-blockers in critical illness.
  • To summarize the impact of beta-blockers on pathophysiology and clinical outcomes across various critical conditions.

Main Methods:

  • Literature review of studies investigating beta-blocker use in critical illness.
  • Analysis of evidence related to hemodynamic, metabolic, and clinical outcomes.

Main Results:

  • Beta-blockers show promise in improving hemodynamic and metabolic parameters.
  • Evidence suggests benefits in burn healing, reduced mortality in traumatic brain injury, and improved outcomes post-cardiac arrest.
  • In sepsis, BBs appear hemodynamically safe post-resuscitation and may enhance cardiac function, with potential to mitigate atrial fibrillation.

Conclusions:

  • Beta-blockers represent a potential therapeutic strategy for managing critical illness.
  • Further research into ultra-rapid BBs may offer new avenues for patient management, particularly in sepsis.